All Monoclonal Antibodies articles – Page 7
-
WebinarDeveloping next generation non-replicative HSV-1 vectors for sustainable and more precise gene therapies
Watch this webinar to learn how the challenges with using certain viral vectors in gene therapy has advanced the development of a new generation of precise vectors with sustainable effects. Our experts outline the limitations of existing vectors and how these can be overcome using modified recombinant non-replicative herpes simplex ...
-
WhitepaperCase Study: Target discovery for rheumatoid arthritis
Learn more about Euretos computational disease model and how it predicts many of the known drug targets for RA.
-
NewsNasal administration of IgA antibodies protects from SARS-CoV-2
Genetic engineering created IgA antibodies that bind to the SARS-CoV-2 spike protein in a similar way to IgG antibodies.
-
WhitepaperArticle: Tips and Tricks for Leveraging Advanced Flow Cytometry
Tips and tricks for fully leveraging Advanced Flow Cytometry.
-
WhitepaperApplication note: Direct and Competitive Live Cell Antibody Binding
Utilizing Advanced High-Throughput Flow Cytometry to Quantify Direct and Competitive Live Cell Antibody Binding
-
NewsAdvancing the development of CTLA-4 inhibitors
A new study could result in CTLA-4 inhibitors that promote antitumour responses without causing intestinal diseases, such as colitis.
-
NewsDelivering a human monoclonal IgG1 antibody to the brain
Adding a biodegradable polymer at the hinge and near hinge regions of trastuzumab enabled its movement across the blood-brain barrier.
-
ArticleThe promise of nanobodies to neutralise the human norovirus
A new discovery about the dynamic structure of norovirus particles has implications for vaccine development.
-
WebinarAdvancing therapeutics targeting cytokines with functional cell-based assays
Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.
-
News
Novel class of antibodies can neutralise multiple strains of flu virus
The new antibodies can neutralise certain H1 and H3 strains with or without the 133a insertion, which could lead to improved vaccines.
-
NewsNew method to induce target-specific immune responses
By fusing antigen proteins into an anchor protein, a specific disease could be targeted without the need to purify the antigen.
-
NewsPancreatic cancer initiates an immune system response
Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
-
WhitepaperHandbook: Advanced flow cytometry handbook
Don’t miss out on the easier way to do flow cytometry. Learn how to bring speed, throughput, multiplexing and miniaturization, to your bench.
-
NewsRare genetic variant blocks common Alzheimer’s disease risk factor
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
-
News
Utilising CAAR T cells to treat antibody-caused brain disease
Researchers have engineered CAAR T cells to destroy harmful antibodies, improving NMDA receptor encephalitis treatment.
-
WebinarComplete aggregate and particle characterisation of protein, gene and cell therapies
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
-
Whitepaperebook: Maximizing preclinical confidence in target efficacy and safety
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
-
WhitepaperGuide: Screening biologic candidates with nanoDSF
Read this guide about nanoDSF for high-resolution measurements of thermal stability parameters, common CQAs for biologics developability assessment.
-
WhitepaperInfographic: Biologics stability in early development
Stability attributes of biologic candidates are evaluated during early development workflows. Learn how to measure them with biophysical techniques.
-
NewsImmunotherapy: antibody set for combating tumours
A recent study sheds light on the potential of artificial DNA structures that, when combined with antibodies, guide the immune system to target cancer cells specifically.